The U.S. Supreme Court issued three decisions Monday, but none of them directly involved pharmaceutical, medical device or diagnostic companies.
There was a decision about the limits of class action arbitration involving a New Jersey doctor, Oxford Health Plans, which is part of UnitedHealthcare, and the U.S. Court of Appeals for the Third Circuit, which is based in Philadelphia. That opinion is here.
Thursday is the next day for opinions to be issued. Usually, the Court issues them on Mondays, but the Justices have a many cases to wrap up by the end of June, when they normally head for vacation.
The three pharma-device-diagnostic cases are:
Gene patenting: Association for Molecular Pathology v. Myriad Genetics, Inc., 12-398. Patent attorney Mercedes Meyer shared some of her thoughts on this case in a PhillyPharma post from earlier today. Link here.
Pay to delay: Federal Trade Commission v. Actavis Pharmaceuticals, 12-416. (Note: Watson Pharmaceuticals was originally the first defendant in the second suit, but Actavis bought Watson earlier this year, so litigation passes to Actavis.)
Lawsuits in state court over product design flaws: Mutual Pharmaceutical Co., v. Bartlett, 12-142.